HORIZONS



Understanding the impact of cancer diagnosis and treatment on everyday life

24 MONTH VULVAL CANCER CRF

FOR STAFF USE ONLY

CRF Completion Instructions

- Please complete as much of the CRF as possible
- Please refer to your copies of previous CRFs when completing this 24 month CRF: please complete any additional treatment details that were not captured at 6 or 12 months (for example, additional treatments, or end dates of those ongoing in earlier CRFs)
- If you have any queries, please contact the HORIZONS
 Co-ordinating Centre, email address <u>HORIZONS@soton.ac.uk</u>
- Please tick boxes when appropriate
- When you have completed the CRF, please keep a copy for your own records and return a copy to us, by post, fax or email along with the completed return cover sheet

Participant's Study ID]/[/						
Participant's date of birth	d	d	m	m	У	У	У	У	I

Has the participant developed any NEW co-morbidities (which were not recorded in any previous CRFs)? (please tick all that apply in the tables below and overleaf)

Myocardial infarct	
Angina/coronary artery disease	
Congestive Heart Failure	
Cardiac Arrythmias	
Hypertension	
Venous Disease (PE/DVT)	
Peripheral Arterial Disease	
Restrictive Lung Disease or COPD (chronic bronchitis, emphysema, asthma etc.)	
Liver Disease (portal hypertension, chronic/acute hepatitis, cirrhosis etc.)	
Stomach Ulcers or Inflammatory Bowel Disease	
Acute or Chronic Pancreatitis	
End-stage Renal Disease (chronic renal insufficiency, dialysis etc.)	
Thyroid problems (hyperthyroidism, hypothyroidism etc.)	
Diabetes Mellitus Type 1	
Diabetes Mellitus Type 2	
Stroke/TIA	
Dementia	
Paralysis (paraplegia or hemiplegia)	
Neuromuscular Condition (multiple sclerosis, Parkinson's, myasthenia gravis, other chronic neuromuscular disorder)	
Clinical diagnosis of anxiety	

Clinical diagnosis of depression	
Psychiatric Diagnosis (e.g. schizophrenia, bipolar disorder)	
Osteoarthritis	
Rheumatoid Arthritis	
Other Rheumatological Disease (systemic lupus, mixed connective tissue disorder, polymyositis, rheumatic polymyositis, scleroderma etc.)	
HIV/AIDS	
Alcohol Abuse (or history of, must be accompanied by social, behavioural or medical com-	

Drug/Substance Abuse (or history of, must be accompanied by social, behavioural or

Other (please give details)

Other (please give details)

Other (please give details) _____

Participant's Study ID

plications)

medical complications)

Morbid Obesity

Is the participant pre or post mo	enopause? (p	lease tick one box)
Pre menopause		
Post menopause		
Unknown		

Participant's Study ID / / /

What treatments has the participant received **since those captured in any previous CRFs**, please tick ALL that apply and write details in the spaces provided. Please add end dates for any treatments which were ongoing previously (table continued overleaf).

Treatment type	Specific treatment details	Tick if patient has re- ceived	Date of surgery or start date of other treatment (dd/mm/yyyy)	End date of treat- ment (if finished) (dd/mm/yyyy)	If course of treat- ment was not completed as planned, please give a reason why	
Neo-adjuvant chemotherapy	Drug(s), please give details		// 20	// 20		
	Neo-adjuvant chemotherapy num	ber of cycles	, please enter on line			
Neo-adjuvant radiotherapy	External radiotherapy		// 20	// 20		
	Number of radiotherapy fractions, please enter on line					
	Dose for each radiotherapy fraction	on please ent	ter on line			

Participant's Study ID	/	/	
Tarticipant 3 Study 15	 	/ _	

Treatment type	Specific treatment details	Tick if patient has re- ceived	Date of surgery or start date of other treatment (dd/mm/yyyy)	End date of treat- ment (if finished) (dd/mm/yyyy)	If course of treat- ment was not completed as planned, please give a reason
Surgery	Sentinel lymph node biopsy		// 20		
	Groin/inguinal lymph node dissection		// 20		
	Radical wide local excision / Wide local excision		// 20		
	Radical partial vulvectomy / Partial vulvectomy		// 20		
	Radical vulvectomy		// 20		
	Pelvic exenteration		// 20		
	Vulval reconstruction		// 20		
	Plastics surgery (please describe)		// 20		
	Other surgery (please describe)				

	 _			
	٦,			
Participant's Study ID	/	/		
i di delpant 3 Stady 15		•		

Treatment type	Specific treatment details	Tick if patient has re- ceived	Date of surgery or start date of other treatment (dd/mm/yyyy)	End date of treat - ment (if fin- ished) (dd/mm/yyyy)	If course of treat - ment was not completed as planned, please give a reason why					
Adjuvant Chemo-	Cisplatin		/ / 20	// 20						
therapy or Chemoradiation	Fluorouracil (5-FU)		/ / 20	// 20						
(please tick all that apply and give details for any radiotherapy	Mitomycin		// 20	// 20						
below)	Carboplatin		/ / 20	/ / 20						
	Paclitaxel/Taxol		// 20	// 20						
	Capcitabine		// 20	/ / 20						
	Other (please describe below):		// 20	/ / 20						
	Chemotherapy number of cy	l cles, please e	l enter on line							
Radiotherapy	External radiotherapy		// 20	// 20						
	Number of radiotherapy fractions, please enter on line									
	Dose for each radiotherapy fraction please enter on line									
	Brachytherapy		// 20	// 20						
	Number of radiotherapy fractions, please enter on line									
	Dose for each radiotherapy	fraction plea	ase enter on line							
Other	Other treatment e.g. clinical trial treatment		// 20	// 20						
	(please describe)									

Participant's	S Study ID	//			
Were any of t	he treatments de	tailed given with	palliative in	tent?	
(please tick on	ne box) Yes	No		Unknown	
If yes, please i	ndicate which tre	atments?			
Has the partic	cipant had a loca	I recurrence of th	neir Vulval ca	ancer? (pleas	e tick one
box)	Yes	No	Unknov	wn	
If the particip	oant has had a lo	cal recurrence, or	n what date	was the recu	rrence
diagnosed?	d d m m	ууууу			
· ·	cipant's diagnosis			nere been any	v evidence
Yes	S	No	Unk	nown	
If you have disease diag	answered "yes" t gnosed:	o the above ques	tion, on wh	at date was th	ne metastatic
	d d	m m y y y	У		
Please provid	e details of the si	te(s) of distant me	etastatic dis	ease:	
Is the participa	ant taking part in	a clinical trial? (p	olease tick o	ne box)	
·	Yes	No	Unkn	own	
-	red "yes" to the a he participant is t		ease give th	e NAME of th	ıe
Name of clini	ical trial				

Participant's Study ID /				
Since the participant's diagnosis of Vulval cancer, have they been diagnosed with another new primary cancer? (please tick one box)				
Yes No	Unknown			
If you answered "yes" to the above questi about the participant's new cancer diagno	•			
Type of cancer				
Date of diagnosis	// 20			
Treatment received				
Date treatment ended (if finished)	// 20			
What type of follow-up care is the participant receiving? (please tick ONE box)				
Routine/regular hospital clinic based follow face-to-face or by telephone)	v-up (medical or nurse led,			
Primary care based follow-up				
Patient initiated follow-up (also known as patient triggered follow-up (PTFU), open access follow-up, or supported self-managed follow-up)				
If the participant is receiving patient-initiated follow-up, on what date were they discharged to this?				

Has the part	t's Study ID / / / / / / / / / / / / / / / / / /
	has been referred to palliative care services please give reason for referral (e.g. end of life care, symptom management)
_	has been referred to psychological services e provide route to referral (e.g. GP, Improving Access to Psychological Therapies)
Participant	has been referred to community services
-	has been referred for treatment related problems (e.g. urology, ology) If ticked, please provide more details below:
Participant	has had an HNA (holistic needs assessment)
Participant's	pant has died please give the date and cause of death: d d / m m / y y y y rticipant's death
1) a)	
1) b)	
1) c)	
2)	
Cause of dea	ath not known
Please add	your name and signature and the date that you completed this CRF
Name	Signature
Date CRF o	